ICN Spin-Off Ribapharm Expects Tiazole Phase III Results By 2002
Ribapharm expects to file an orphan drug application for the myelogenous leukemia treatment Tiazole (tiazofurin) following completion of a Phase III trial by the end of 2002.
Ribapharm expects to file an orphan drug application for the myelogenous leukemia treatment Tiazole (tiazofurin) following completion of a Phase III trial by the end of 2002.